NEW YORK / Jun 01, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the following investor conferences in June 2023:
Company executives will take part in a fireside chat at the 2023 Jefferies Healthcare Conference in New York, New York on June 8, 2023. They will answer questions about the company at 9:00 a.m. ET.
Bristol Myers Squibb executives will also participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023, in Dana Point, California. They will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET.
Investors and the general public are invited to listen to a live webcast of both sessions during their respective times at http://investor.bms.com. An archived edition of each session will be available later the same day it occurs.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$45.02 |
| Daily Change: | -0.58 -1.27 |
| Daily Volume: | 23,259,305 |
| Market Cap: | US$91.840B |
August 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
